Osteoporosis
Conditions
Interventions
Hyperlipidemia group:No intervention
No hyperlipidemia group:No intervention
Sponsors
The First Affiliated Hospital of Guangdong Pharmaceutical University
Eligibility
Sex/Gender
All
Age
45 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Natural postmenopausal women who were treated in our hospital, aged 45 to 80; 2. The female subjects had a clear consciousness, were able to understand and cooperate with the completion of the bone mineral density test, and completed the questionnaire survey, with clear answers, and informed consent to this study.
Exclusion criteria
Exclusion criteria: 1. Have used zoledronate in the past 1 year, used denosumab in the past six months, oral bisphosphonates, anti-osteoporosis traditional Chinese medicine preparations such as Hugu Capsule, Jintiange Capsule, etc. have been discontinued less than 3 months; 2. Secondary OP or a history of fracture within the past 1 year; 3. Exclude rheumatoid arthritis, osteoarthritis, diabetes, gastrointestinal diseases, etc.; 4. Severe heart, liver, kidney and other organ dysfunction, blood system, and autoimmune diseases, acute and chronic infections, malignant tumors or severe mental illness; 5. History of combined thyroid, pituitary, hypothalamus and other endocrine diseases; 6. Taking hormones such as glucocorticoids, sex hormones, active vitamin D, fluoride, antiepileptic drugs, etc. all year round; 7. Those who participate in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in bone mineral density measured at week 48;Absolute value of changes in blood lipids (TC, TG, LDL, DHL, ) at week 48;Absolute value of BMI change at week 48;Absolute value of change in waist and hip circumference at week 48;TCM symptom score; | — |
Countries
China
Contacts
Public ContactGuo Jiao
The First Affiliated Hospital of Guangdong Pharmaceutical University
Outcome results
None listed